Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

D-915

Supelco

Desalkylflurazepam solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C15H10ClFN2O
Número CAS:
Peso molecular:
288.70
Número CE:
Número MDL:
Código UNSPSC:
41116107
NACRES:
NA.24

grau

certified reference material

Nível de qualidade

Formulário

liquid

Características

Snap-N-Spike®/Snap-N-Shoot®

embalagem

ampule of 1 mL

fabricante/nome comercial

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland)

concentração

1.0 mg/mL in methanol

técnica(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

aplicação(ões)

clinical testing

Formato

single component solution

temperatura de armazenamento

−20°C

cadeia de caracteres SMILES

Fc1ccccc1C2=NCC(=O)Nc3ccc(Cl)cc23

InChI

1S/C15H10ClFN2O/c16-9-5-6-13-11(7-9)15(18-8-14(20)19-13)10-3-1-2-4-12(10)17/h1-7H,8H2,(H,19,20)

chave InChI

UVCOILFBWYKHHB-UHFFFAOYSA-N

Categorias relacionadas

Descrição geral

Desalkylflurazepam, also known as N-desalkyl-2-oxoquazepam, is a long-acting metabolite of the benzodiazepine drug flurazepam. Flurazepam is sold unde the trade names Dalmane and Dalmadorm for the treatment of mild to moderate insomnia. This Certified Spiking Solution® is suited for use in LC/MS or GC/MS applications for clinical toxicology, forensic analysis or urine drug testing.

Informações legais

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Palavra indicadora

Danger

Classificações de perigo

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Órgãos-alvo

Eyes,Central nervous system

Código de classe de armazenamento

3 - Flammable liquids

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

49.5 °F - closed cup

Ponto de fulgor (°C)

9.7 °C - closed cup


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

J Hilbert et al.
Drug metabolism and disposition: the biological fate of chemicals, 12(4), 452-459 (1984-07-01)
The disposition of 14C-quazepam (7-chloro-(2,2,2-trifluoroethyl) [5-14C]-5-o-fluorophenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-thione), a new benzodiazepine hypnotic, was studied in hamsters and mice after iv and po dosing. In both species, quazepam was rapidly absorbed, as indicated by the plasma Cmax being reached within 1 hr of
Y Sakai et al.
Japanese journal of pharmacology, 37(4), 373-379 (1985-04-01)
A new benzodiazepine compound, ethyl loflazepate (ethyl-7-chloro-2,3-dihydro-5-(2-fluorophenyl)-2-oxo-1H,1,4- benzodiazepine-3-carboxylate; CM6912) was studied using in vitro experimental systems for its displacement activity on 3H-diazepam binding to the synaptosomal membrane fraction of rat cerebrum and potentiating action on GABA. CM6912 inhibited the specific
S K Gupta et al.
Pharmaceutical research, 5(6), 365-368 (1988-06-01)
A reverse-phase liquid chromatographic method is described for simultaneous quantification of quazepam, and two of its metabolites, 2-oxoquazepam and N-desaklyl-2-oxoquazepam. The method uses a solid-phase extraction procedure to prepare plasma samples. After extraction, the methanolic extract is evaporated; the residue
J M Hilbert et al.
Clinical pharmacology and therapeutics, 36(4), 566-569 (1984-10-01)
The kinetics of quazepam, a benzodiazepine hypnotic, was studied in 10 geriatric subjects. Each received one 15-mg tablet of quazepam. Blood samples were collected before and at specified times (up to 672 hr) after dosing. Plasma concentrations of quazepam and
K Schaffler et al.
Arzneimittel-Forschung, 39(2), 276-283 (1989-02-01)
To assess pharmacodynamic and pharmacokinetic properties of acute, subchronic and withdrawn quazepam, a single-blind, longitudinal study was run in eight male, healthy young volunteers. The design covered a 1-week placebo run-in period, a period with daily oral night-time administration of

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica